1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
GlycoNex, Inc.

GlycoNex, Inc.

TTPEX:4168
21.45
TWD
-0.30
(-1.38%)
-2.43EPS
2.88BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.55
0.1
0.09
- -
0.01
0.01
0.01
0.01
0.06
0.3
0.02
0.14
0.35
0.2
Basic EPS, GAAP
-0.33
-0.53
-1.01
-1.27
-1.9
-4.15
-3.23
-1.82
-1.78
-2.2
-1.65
-2.12
-2.16
-2.43
Free Cash Flow per Basic Share
-2.12
-2.7
-9.91
-3.21
-2.53
-2.4
-2.37
-1.65
-1.52
-1.77
-1.92
-2.38
-1.59
-1.81
Dividend per Share
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
30.41
29.02
27.69
25.57
24.15
20.05
16.99
15.73
13.88
13.46
11.77
9.65
8.73
7.56
Tangible Book Value per Share
30.1
27.97
26.79
24.83
23.55
19.84
16.92
15.73
13.88
13.46
11.77
9.61
8.68
7.52
Basic Weighted Avg Shares
65
77
76
76
76
76
77
90
97
100
108
108
109
111
Sales/Revenue/Turnover
36
8
7
- -
1
1
1
- -
5
30
3
15
38
22
Operating Margin (%)
-76.45
-765.02
-1,249.69
-43,610.88
-25,366.4
-34,727.97
-36,766.08
-47,476.5
-3,560.33
-793.22
-10,222.82
-1,674.14
-659.81
-1,342.98
Depreciation Expense
9
12
30
36
53
57
55
47
40
40
31
34
35
36
Net Income, GAAP
-21
-41
-77
-97
-145
-317
-247
-163
-172
-220
-178
-230
-235
-270
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-60.05
-525.26
-1,107.54
-40,752.72
-22,805.68
-34,227.11
-33,682.15
-36,082.26
-3,150.56
-730.67
-7,016.6
-1,562.51
-621.29
-1,217.39
Working Capital
1,935
1,886
1,061
884
579
341
165
474
331
669
448
217
655
543
LT Debt
15
- -
- -
- -
- -
- -
- -
- -
- -
219
- -
- -
474
478
Total Equity
2,314
2,219
2,117
1,986
1,841
1,532
1,301
1,540
1,359
1,446
1,276
1,046
982
851
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-1.34
-1.82
-3.56
-4.75
-7.55
-18.79
-17.45
-11.46
-11.9
-15.68
-13.11
-19.78
-23.19
-29.27

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1
- -
2
LT Borrowings
474
476
478
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
113
113
113
Market Capitalization
2,897
2,594
2,881

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
748
656
601
Cash, Cash Equivalents & STI
693
612
568
Accounts Receivable, Net
2
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
93
67
57
Payables & Accruals
- -
- -
- -
ST Debt
1
- -
2
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-6.82%
-8.24%
-6.13%
Free Cash Flow
-8.53%
5.68%
-32.8%
Net Income, GAAP
18.36%
9.15%
2.4%
Sales/Revenue/Turnover
216.32%
421.56%
157.54%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9
- -
2
3
15
2025
14
16
4
4
38
2026
12
2
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.67
-0.46
-0.41
-0.58
-2.12
2025
-0.41
-0.47
-0.55
-0.72
-2.16
2026
-0.67
-0.49
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Mei Chun Yang
Full Time Employees
25
Sector
Health technology
Industry
Biotechnology
Address
No. 97, Xintai 5th Road New Taipei NWT Taiwan 22175
IPO Date
Dec 16, 2011
Website
glyconex.com.tw
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
GlycoNex Incorporation is a biotechnology company primarily engaged in the development, manufacturing, and sales of innovative glycan-based products and solutions. Its core offerings include glycan reagents for research and diagnostics; glycan profiling and analysis services; bioactive glycan compounds; and custom glycan synthesis for pharmaceutical and life sciences applications. The company provides its products and services to academic research institutions, pharmaceutical companies, and diagnostic developers within Taiwan and internationally. Founded in 2005, GlycoNex is headquartered in Taipei, Taiwan. In the last 1-2 years, GlycoNex has made strategic expansions through partnerships with key pharmaceutical firms to accelerate its glycan biomarker discovery programs and has launched a new range of advanced glycan profiling kits aimed at enhancing precision diagnostics. GlycoNex has also enhanced its custom synthesis capabilities through recent investments in state-of-the-art manufacturing technologies, positioning itself as a leading glycomics solutions provider in the Asia-Pacific region. These developments reflect GlycoNex's commitment to innovation and its expansion into broader markets within the biotechnology and healthcare sectors.